Foghorn Therapeutics (FHTX) Capital Leases (2021)
Foghorn Therapeutics' (FHTX) quarterly Capital Leases came in at $198000.0 in Q2 2021, down 12.0% quarter-over-quarter from $225000.0 in Q1 2021.
Foghorn Therapeutics (FHTX) Capital Leases (2021) Analysis & Trends
Foghorn Therapeutics' Capital Leases history runs 1 years deep, the most recent figure standing at $198000.0 for Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 198,000.00 |
| Mar 31, 2021 | 225,000.00 |